BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hays EM, Duan W, Shigdar S. Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications. Int J Mol Sci 2017;18:E2576. [PMID: 29189740 DOI: 10.3390/ijms18122576] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Sa P, Sahoo SK. Recent advances in aptamer-based nanomaterials in imaging and diagnostics of cancer. Aptamers Engineered Nanocarriers for Cancer Therapy 2023. [DOI: 10.1016/b978-0-323-85881-6.00007-5] [Reference Citation Analysis]
2 Yin X, He Z, Ge W, Zhao Z. Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors. Front Bioeng Biotechnol 2023;11:1092901. [PMID: 36873354 DOI: 10.3389/fbioe.2023.1092901] [Reference Citation Analysis]
3 Grover R, Drall S, Poonia N, Kumar Jain G, Aggarwal G, Lather V, Kesharwani P, Pandita D, Goyal RK. CD44 and CD133 aptamer directed nanocarriers for cancer stem cells targeting. European Polymer Journal 2023;183:111770. [DOI: 10.1016/j.eurpolymj.2022.111770] [Reference Citation Analysis]
4 Sankar Satpathy B, Barik B, Alik Kumar L, Biswal S. Potential of Lipid Based Nanodrug Carriers for Targeted Treatment of Glioblastoma: Recent Progress and Challenges Ahead. Glioblastoma - Current Evidences [Working Title] 2022. [DOI: 10.5772/intechopen.108419] [Reference Citation Analysis]
5 Madani F, Esnaashari SS, Webster TJ, Khosravani M, Adabi M. Polymeric nanoparticles for drug delivery in glioblastoma: State of the art and future perspectives. J Control Release 2022;349:649-61. [PMID: 35878729 DOI: 10.1016/j.jconrel.2022.07.023] [Reference Citation Analysis]
6 Sarafraz M, Nakhjavani M, Shigdar S, Christo FC, Rolfe B. Modelling of Mass Transport and Distribution of Aptamer in Blood-Brain Barrier (BBB) Domain for Tumour Therapy and Cancer Treatment. European Journal of Pharmaceutics and Biopharmaceutics 2022. [DOI: 10.1016/j.ejpb.2022.03.004] [Reference Citation Analysis]
7 Nakhjavani M, Samarasinghe RM, Shigdar S. Triple-negative breast cancer brain metastasis: an update on druggable targets, current clinical trials, and future treatment options. Drug Discovery Today 2022. [DOI: 10.1016/j.drudis.2022.01.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Moharir KS, Kale V, Kurakula M. Nanotherapeutic systems for drug delivery to brain tumors. Photophysics and Nanophysics in Therapeutics 2022. [DOI: 10.1016/b978-0-323-89839-3.00002-6] [Reference Citation Analysis]
9 Wu Z, Dai L, Tang K, Ma Y, Song B, Zhang Y, Li J, Lui S, Gong Q, Wu M. Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics. Regen Biomater 2021;8:rbab062. [PMID: 34868634 DOI: 10.1093/rb/rbab062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
10 Nakhjavani M, Shigdar S. Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer. Pharmacol Res 2021;175:106019. [PMID: 34861397 DOI: 10.1016/j.phrs.2021.106019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Sabbih GO, Danquah MK. Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting. Int J Mol Sci 2021;22:9101. [PMID: 34445807 DOI: 10.3390/ijms22169101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Vorobyeva MA, Dymova MA, Novopashina DS, Kuligina EV, Timoshenko VV, Kolesnikov IA, Taskaev SY, Richter VA, Venyaminova AG. Tumor Cell-Specific 2'-Fluoro RNA Aptamer Conjugated with Closo-Dodecaborate as A Potential Agent for Boron Neutron Capture Therapy. Int J Mol Sci 2021;22:7326. [PMID: 34298946 DOI: 10.3390/ijms22147326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Shigdar S, Schrand B, Giangrande PH, de Franciscis V. Aptamers: Cutting edge of cancer therapies. Mol Ther 2021;29:2396-411. [PMID: 34146729 DOI: 10.1016/j.ymthe.2021.06.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
14 Bell M, Rooks CP, Agrahari V. Drug Delivery Approaches and Imaging Techniques for Brain Tumor. Neuromethods 2021. [DOI: 10.1007/978-1-0716-1052-7_4] [Reference Citation Analysis]
15 Nur Topkaya S, Cetin AE. Electrochemical Aptasensors for Biological and Chemical Analyte Detection. Electroanalysis 2021;33:277-91. [DOI: 10.1002/elan.202060388] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
16 Amero P, Khatua S, Rodriguez-Aguayo C, Lopez-Berestein G. Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology. Cancers (Basel) 2020;12:E2889. [PMID: 33050158 DOI: 10.3390/cancers12102889] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
17 Ravichandran G, Rengan AK. Aptamer-Mediated Nanotheranostics for Cancer Treatment: A Review. ACS Appl Nano Mater 2020;3:9542-59. [DOI: 10.1021/acsanm.0c01785] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
18 Cesarini V, Scopa C, Silvestris DA, Scafidi A, Petrera V, Del Baldo G, Gallo A. Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma. Molecules 2020;25:E4267. [PMID: 32957732 DOI: 10.3390/molecules25184267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Czechowska K, Lannigan J, Wang L, Arcidiacono J, Ashhurst TM, Barnard RM, Bauer S, Bispo C, Bonilla DL, Brinkman RR, Cabanski M, Chang HD, Chakrabarti L, Chojnowski G, Cotleur B, Degheidy H, Dela Cruz GV, Eck S, Elliott J, Errington R, Filby A, Gagnon D, Gardner R, Green C, Gregory M, Groves CJ, Hall C, Hammes F, Hedrick M, Hoffman R, Icha J, Ivaska J, Jenner DC, Jones D, Kerckhof FM, Kukat C, Lanham D, Leavesley S, Lee M, Lin-Gibson S, Litwin V, Liu Y, Molloy J, Moore JS, Müller S, Nedbal J, Niesner R, Nitta N, Ohlsson-Wilhelm B, Paul NE, Perfetto S, Portat Z, Props R, Radtke S, Rayanki R, Rieger A, Rogers S, Rubbens P, Salomon R, Schiemann M, Sharpe J, Sonder SU, Stewart JJ, Sun Y, Ulrich H, Van Isterdael G, Vitaliti A, van Vreden C, Weber M, Zimmermann J, Vacca G, Wallace P, Tárnok A. Cyt-Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2018 Conference Workshops. Cytometry A 2019;95:598-644. [PMID: 31207046 DOI: 10.1002/cyto.a.23777] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
20 Nuzzo S, Brancato V, Affinito A, Salvatore M, Cavaliere C, Condorelli G. The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature. Cancers (Basel) 2020;12:E2173. [PMID: 32764266 DOI: 10.3390/cancers12082173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
21 Wang W, Lv W, Pan Z, Zhan L, Huang C. FRET-enhanced nanoflares for sensitive and rapid detection of ampicillin. Anal Methods 2020;12:970-6. [DOI: 10.1039/d0ay00081g] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
22 Chatterji U. Lung Cancer: Old Story, New Modalities! Oxidative Stress in Lung Diseases 2020. [DOI: 10.1007/978-981-32-9366-3_17] [Reference Citation Analysis]
23 Mazur J, Roy K, Shigdar S, Kanwar JR. Efficacy of promising flavonoids from Festuca, Lonicera, and Acacia genera against glioblastoma multiforme; potential for the Dandenong Ranges. Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents 2020. [DOI: 10.1016/b978-0-12-819666-3.00013-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Fu Q, Shaya M, Li S, Kugeluke Y, Dilimulati Y, Liu B, Zhou Q. Analysis of clinical characteristics of macrophage capping protein (CAPG) gene expressed in glioma based on TCGA data and clinical experiments. Oncol Lett 2019;18:1344-50. [PMID: 31423196 DOI: 10.3892/ol.2019.10396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
25 Shirian S, Khetvan-hafshejani R, Ali E, Modarres Mousavi M, Abdollahi S, Lotfi Bakhshaiesh N, Department of Pathobiology, School of Veterinary Medicine, Shahrekord University, Shahrekord, Iran, Department of Pathobiology, School of Veterinary Medicine, Shahrekord University, Shahrekord, Iran, Department of Pharmacology, Qazvin University of Medical Sciences, Qazvin, Iran, a. Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. b Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran, a. Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran. b. Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran, Department of Tissue Engineering, Faculty of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. The Role of Aptamers in the Treatment of Glioblastoma Multiform. Shefaye Khatam 2019;7:91-105. [DOI: 10.29252/shefa.7.1.91] [Reference Citation Analysis]
26 Khalid U, Vi C, Henri J, Macdonald J, Eu P, Mandarano G, Shigdar S. Radiolabelled Aptamers for Theranostic Treatment of Cancer. Pharmaceuticals (Basel) 2018;12:E2. [PMID: 30586898 DOI: 10.3390/ph12010002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
27 Vandghanooni S, Eskandani M, Barar J, Omidi Y. Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective. J Mol Med (Berl) 2018;96:885-902. [PMID: 30056527 DOI: 10.1007/s00109-018-1669-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]